


## AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

### Listing of Claims

1. (Currently amended) A compound of formula I:



I

wherein:

R<sup>1</sup> = H

R<sup>2</sup> = -OH, -OR<sup>5</sup>, -OCH<sub>2</sub>C(O)R<sup>5</sup>, -OCH<sub>2</sub>C(O)NHR<sup>5</sup>, -OC(O)R<sup>5</sup>, -OC(O)NHNH-R<sup>5</sup>, or -OC(O)NR<sup>5</sup>R<sup>6</sup>, where R<sup>5</sup> is H, C<sub>1</sub>-C<sub>20</sub> alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, or alkylaryl, and where R<sup>5</sup> can optionally contain hydrogen atoms;

R<sup>3</sup> and R<sup>4</sup>, the same or different from each other, are C<sub>1</sub>-C<sub>20</sub> alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R<sup>2</sup> is -OH, -OCH<sub>3</sub>, or -OC(O)CF<sub>3</sub> and R<sup>3</sup> R<sup>4</sup> is -CH<sub>3</sub>, then R<sup>4</sup> R<sub>4</sub> is not -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>), or -CH=CH-CH<sub>3</sub>, and

and the further proviso that when R<sup>3</sup> is -CH<sub>2</sub>-(C<sub>6</sub>H<sub>5</sub>), then R<sup>4</sup> is not -CH<sub>3</sub> or -CH<sub>2</sub>CH<sub>3</sub>.

2. (Original) A compound according to claim 1, wherein R<sup>5</sup> is H, C<sub>1</sub>-C<sub>10</sub> alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

3. (Original) A compound according to claim 2, wherein R<sup>5</sup> is H, or C<sub>1</sub>-C<sub>10</sub> alkyl.


4. (Original) A compound according to claim 1, wherein R<sup>3</sup> and R<sup>4</sup> are each independently H, C<sub>1</sub>-C<sub>10</sub> alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.


5. (Original) A compound according to claim 1, wherein  $R^3$  and  $R^4$  are each independently H or  $C_1$ - $C_{10}$  alkyl.

6. (Original) A compound according to claim 1, wherein  $R^3$  is -H or  $-CH_3$ .

7. (Original) A compound according to claim 1, wherein  $R^4$  is  $-nC_6$ - $C_8$  alkyl.

8. (Currently amended) A compound according to claim 1, wherein the compound is selected from the group consisting of:





Claims 9-17 (Cancelled)

Claim 18 (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I.


Claims 19-25 (Cancelled)

26. (Original) A method of treating cancer in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 16 to said subject.


27. (Original) The method of claim 26, wherein the subject is a human.

28. (Original) The method of claim 26, wherein the subject is an animal.

29. (Original) The method of claim 27, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:



30. (Original) The method of claim 28, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:



Claims 31-38 (Cancelled)

39. (Original) A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 16 to said subject.

40. (Currently amended) The method of claim 16 39, wherein the subject is a human.


41. (Currently amended) The method of claim 16 39, wherein the subject is an animal.

42. (Original) A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 16 to said subject.


43. (Original) The method of claim 42, wherein the subject is a human.

44. (Original) The method of claim 42, wherein the subject is an animal.


45. (Original) The method of claim 43, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:



46. (Original) The method of claim 43, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




47. (new) A compound of formula:



48. (New) A pharmaceutical composition comprising a pharmaceutical diluent and the compound of claim 47.

49. (New) A method of treating cancer in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 47.


50. (New) A compound of formula:



51. (New) A pharmaceutical composition comprising a pharmaceutical diluent and the compound of claim 50.

52. (New) A method of treating cancer in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 51.

53. (New) A compound of formula:



54. (New) A pharmaceutical composition comprising a pharmaceutical diluent and the compound of claim 53.

55. (New) A method of treating cancer in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 54.

56. (New) A compound according to claim 1, where:

$R^1$  is H;

$R^2$  is  $-OCH_2C(O)NHR^5$ , where  $R^5$  is  $C_1$ - $C_{10}$  aryl containing a halogen atom;


$R^3$  is  $-CH_3$ ;

$R^4$  is  $-n-C_6-C_8$  alkyl;

57. (New) A pharmaceutical composition comprising a pharmaceutical diluent and the compound of claim 56.

58. (New) A method of treating cancer in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 56.

59. (New) A compound of formula IV:



wherein:

$R^{29} = H$

$R^{30} = -OH, -OR^{33}, -OCH_2C(O)R^{33}, -OCH_2C(O)NHR^{33}, -OC(O)R^{33}, -OC(O)NHNH-R^{33},$   
or  $-OC(O)NR^{33}R^{34}$ , where  $R^{33}$  and  $R^{34}$  are each independently H,  $C_1$ - $C_{20}$  alkyl,



cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, or alkylaryl, and where  $R^5$  can optionally contain hydrogen atoms;

$R^{31}$  and  $R^{32}$ , the same or different from each other, are  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when  $R^{30}$  is  $-OH$ ,  $-OCH_3$ , or  $-OC(O)CF_3$  and  $R^{31}$  is  $-CH_3$ , then

$R^{32}$  is not  $-CH_2CH_2OH$ ,  $-CH_2(C_6H_5)$ , or  $-CH=CH-CH_3$ , and

the further proviso that when  $R^{31}$  is  $-CH_2-(C_6H_5)$ , then  $R^{32}$  is not  $-CH_3$  or  $-CH_2CH_3$ .

60. (New) A compound according to claim 59, wherein  $R^{33}$  is H,  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, aryl, arylalkyl, or alkylaryl.

61. (New) A compound according to claim 60, wherein  $R^{33}$  is H, or  $C_1$ - $C_{10}$  alkyl.

62. (New) A compound according to claim 59, wherein  $R^{31}$  and  $R^{32}$  are each independently H,  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, aryl, arylalkyl, or alkylaryl.

63. (New) A compound according to claim 62, wherein  $R^{31}$  and  $R^{32}$  are each independently H, or  $C_1$ - $C_{10}$  alkyl.

64. (New) A compound according to claim 59, wherein  $R^{31}$  is  $-H$  or  $-CH_3$ .

65. (New) A compound according to claim 59, wherein  $R^{32}$  is  $-nC_6-C_8$  alkyl.

66. (New) A compound according to claim 59, wherein the compound has the formula:

